ATMA CENA is a Canadian clinical mental-health network offering Health-Canada-regulated and Special-Access-Program (SAP) pathways into psychedelic-assisted therapy — off-label ketamine, Health-Canada-approved esketamine (Spravato), and SAP-pathway psilocybin and MDMA, paired with structured psychotherapy and integration. The patients we serve are not a single population. They are veterans carrying combat- and operational-trauma; first responders with cumulative occupational PTSD; LGBTQ+ Canadians whose mental-health burden is shaped by minority stress; older adults with treatment-resistant late-life depression; couples whose trauma lives between them; healthcare workers carrying moral injury; family members seeking to support a loved one; Indigenous patients navigating clinical pathways while preserving the integrity of traditional medicine traditions; Canadians with disabilities for whom accessibility is a structural prerequisite to care. They are not, in our practice, adolescents, pregnant patients, or anyone in active mania, active psychosis, or acute medical instability — not because those Canadians do not deserve excellent mental-health care, but because the evidence base, regulatory framing, and harm-reduction calculus in those situations point toward specialized care first.

This page is the navigational overview above ATMA CENA's nine population guides. It is not a depth document — each guide is its own clinical article. It is the honest summary: who we work with, who we do not, and where the cross-cutting populations (veterans and first responders) sit relative to our substance and insurance resources.

Crisis resources — please read first

If you or someone you love is in crisis, please reach out before reading further:

9-8-8 Canada Suicide Crisis Helpline — call or text 9-8-8, 24/7, in English and French. https://988.ca/

Talk Suicide Canada — 1-833-456-4566, 24/7. Text 45645 (4 PM–midnight ET). https://talksuicide.ca/

Hope for Wellness Helpline (Indigenous; First Nations, Inuit, Métis) — 1-855-242-3310, 24/7, in English, French, Cree, Ojibway, Inuktitut. https://www.hopeforwellness.ca/

Trans Lifeline (Canada) — 1-877-330-6366, peer-staffed by and for trans people. https://translifeline.org/hotline/

Kids Help Phone — 1-800-668-6868 (24/7); text CONNECT to 686868. https://kidshelpphone.ca/

If you or someone you love is in immediate medical danger, call 911 or attend your nearest emergency department.

Crisis resources are not optional add-ons. Many Canadians who eventually become ATMA CENA patients first encounter mental-health care during a crisis call. We will always route to crisis services first when clinical urgency requires it.

Key takeaways

ATMA CENA works with adult Canadian populations — generally age 18 and older, medically and psychiatrically appropriate, with conditions for which one or more of our pathways (Spravato, off-label ketamine, SAP (Special Access Program) psilocybin or MDMA) is clinically indicated.

Nine population guides are linked below: older adults, couples/dyadic, Indigenous & culturally-responsive, LGBTQ+, family members, adolescents/young adults (contraindicated populations), healthcare workers/therapists, pregnancy/postpartum (contraindicated populations), and disability/accessibility.

Two cross-cutting populations — veterans and first responders — do not have dedicated population guides; their depth lives in our VAC coverage, MDMA-AT for veterans, workers' compensation, and first-responder presumptive PTSD legislation articles.

Caveat populations are flagged honestly — adolescents under 18 and pregnant or lactating patients are most often contraindicated for psychedelic-assisted therapy under current evidence and Health Canada framing; specialized care is the right pathway.

Populations providers generally cannot safely serve include patients in active mania, active psychosis, severe medical instability, and (with limited exceptions) those who lack capacity to consent.

Cultural humility, affirming care, and accessibility are baseline standards — not add-ons — for Indigenous, LGBTQ+, and disability populations respectively. Bill C-4 (in force January 7, 2022) makes the use of psychedelic-assisted therapy as a conversion practice a criminal offence in Canada.

Crisis resources are foundational and apply to every population covered here.

The coordinated care overlay — ATMA CENA's structured care pathway — adapts within population-specific boundaries.

How to read this hub

ATMA CENA's population landscape is best navigated by who you are or whom you support. Each section below is a short overview that:

names the population and its clinical context,
summarizes the Canadian evidence base honestly,
flags the population-specific safety considerations,
links — with descriptive anchors — to the dedicated guide article for the depth and the citations,
notes the relevant insurance, workers'-compensation, or VAC pathway where applicable.

You may sit in more than one population. A 70-year-old Indigenous veteran with PTSD belongs at the intersection of older adults, Indigenous & culturally-responsive care, and the cross-cutting veterans pathway. A 32-year-old paramedic with a family member in psychedelic-assisted therapy belongs at the intersection of first responders and family members. We expect these intersections — and we treat them as the rule, not the exception.

Older adults (age 65+)

Older adults carry a substantial mental-health burden — late-life depression, post-traumatic stress disorder (PTSD, including aging veterans, residential-school survivors, and lifetime-trauma cohorts), end-of-life distress in advanced or terminal illness, generalized anxiety, and treatment-resistant depression (TRD) accumulated across decades. Older men carry the highest suicide rates of any Canadian demographic.

The pivotal psychedelic-assisted therapy RCT base has historically excluded older adults. The COMP001 phase 2b trial (Goodwin 2022, NEJM) of single-dose psilocybin for treatment-resistant depression enrolled participants aged 18–65. The Mitchell 2021 (MAPP1) and Mitchell 2023 (MAPP2) phase 3 MDMA-assisted therapy trials in PTSD likewise capped enrolment at adult cut-offs that under-represented patients above 65. The most directly applicable older-adult evidence comes from end-of-life distress psilocybin trials in cancer patients — Griffiths 2016 and Ross 2016 (both Journal of Psychopharmacology) — and from the Anand 2023 ELEKT-D trial (NEJM) of ketamine versus electroconvulsive therapy in non-psychotic treatment-resistant depression, which included older patients.

Geriatric medicine treats functional age and comorbidity, not chronological age. The clinical foundation for any older-adult psychedelic-assisted therapy plan is a comprehensive geriatric assessment — medical, functional, cognitive, social, and a Beers-criteria medication review for polypharmacy and anticholinergic burden. Cardiovascular screening is essential: ketamine and esketamine produce acute blood-pressure and heart-rate elevations; MDMA produces sustained sympathomimetic load; older adults carry higher baseline cardiovascular comorbidity. Cognitive screening matters: pre-existing impairment, dementia, and delirium risk shift the risk–benefit calculus substantially. The Canadian Coalition for Seniors' Mental Health (CCSMH) guidelines provide the standard-of-care framework for late-life depression.

For the comprehensive Canadian geriatric guide, including pharmacology detail, RCT inclusion data, and Quebec-RAMQ / VAC / public-hospital ketamine pathways, see our older adults psychedelic therapy guide.

Couples and dyadic psychedelic-assisted therapy

Some patients arrive at ATMA CENA not alone but with a partner. Trauma frequently lives between people — a veteran's PTSD reshapes the home; a cancer diagnosis reshapes a marriage; complex relational trauma reshapes attachment. Dyadic psychedelic-assisted therapy is an emerging clinical model with a small but meaningful evidence base.

The principal published trial is Monson et al. 2020 in European Journal of Psychotraumatology: an uncontrolled trial of MDMA-facilitated cognitive-behavioural conjoint therapy (CBCT) for PTSD, in which six couples completed a condensed 15-session protocol with two MDMA-assisted dyadic sessions. PTSD symptoms, depression, sleep, emotion regulation, and relationship adjustment all improved with large effect sizes. The follow-up paper Wagner et al. 2021 in Frontiers in Psychiatry described relational and growth outcomes from the same cohort. The evidence is preliminary; the model is promising; the framing is honest.

Dyadic care is not for every couple. Active intimate-partner violence, severe imbalance in capacity for informed consent between partners, and unresolved acute psychiatric instability in either partner are clinical contraindications to a dyadic protocol. For couples and dyads — including caregiver-patient pairs facing serious illness — see our couples and dyadic psychedelic therapy guide.

Indigenous patients and culturally-responsive care

Indigenous Peoples in Canada — First Nations, Inuit, and Métis — represent approximately 5% of the population. Mental-health need in this group cannot be understood without the historical and structural context: residential schools (operated until the last federally-funded school closed in 1996), the Sixties Scoop, the Indian-hospital system, ongoing systemic racism in health care (as documented in the In Plain Sight report and in the death of Joyce Echaquan), and intergenerational trauma. Indigenous youth suicide rates are substantially elevated relative to the general Canadian youth population.

The Truth and Reconciliation Commission's Calls to Action 18–24 (2015) name closing health-outcome gaps and recognizing Indigenous healing practices alongside Western medicine as obligations. Two-Eyed Seeing (Etuaptmumk), articulated by Mi'kmaq Elder Albert Marshall, frames Indigenous and Western knowledge as two eyes that, together, see further than either alone. Cultural humility — lifelong self-reflection, power analysis, and partnership — has displaced "cultural competence" as the more honest stance. The Roots to Thrive / Snuneymuxw First Nation collaboration in Nanaimo, BC is a cited example of a clinical–community partnership advanced with explicit consent and Indigenous leadership.

ATMA CENA's stance is unambiguous: Indigenous healing traditions are ancient, sovereign, and distinct from clinical psychedelic-assisted therapy. We do not offer ceremony, traditional knowledge, or Indigenous healing. We offer Health-Canada-regulated and SAP-pathway clinical care within a culturally-humble framework. The honest distinction between clinical psychedelic-assisted therapy and Indigenous traditional medicine is the foundation of practising in this space without appropriation. NIHB (Non-Insured Health Benefits program) through Indigenous Services Canada covers some mental-health counselling for eligible First Nations and Inuit clients; psychedelic-assisted therapy itself is not a covered NIHB benefit at this time.

For the Canadian guide — TRC framing in detail, Two-Eyed Seeing application, the Roots to Thrive partnership, NIHB and FNIHB context, VAC for Indigenous veterans, and how ATMA CENA practises cultural humility concretely — see our Indigenous and culturally-responsive psychedelic therapy guide.

LGBTQ+ patients — affirming care as a baseline

LGBTQ+ Canadians (lesbian, gay, bisexual, trans, nonbinary, queer, two-spirit, intersex, asexual, and other sexual and gender minority identities) carry a substantially elevated burden of mental-health need relative to cisgender heterosexual peers. Statistics Canada and the peer-reviewed literature document roughly two-fold elevations in major depressive episodes, two-to-four-fold elevations in PTSD, substantially elevated suicidality, and elevated substance-use disorder prevalence. Trans and nonbinary Canadians carry the highest elevations.

The dominant explanatory framework is minority stress (Meyer 2003, Psychological Bulletin): chronic exposure to stigma, prejudice, and discrimination produces cumulative mental-health load through both distal stressors (hate crime, structural exclusion) and proximal stressors (internalized stigma, concealment). MDMA-assisted therapy for PTSD (Mitchell 2021, 2023) is particularly relevant given trauma prevalence in this population.

Affirming care is a baseline standard, not an add-on: pronoun and chosen-name use, family-of-choice integration, alignment with the WPATH Standards of Care, version 8 (Coleman et al. 2022, International Journal of Transgender Health) for trans health. HRT (estradiol, testosterone) interactions with psychedelics are not extensively published; clinically the documented interactions are minimal but warrant individualized review. Antiretroviral therapy interactions — particularly ritonavir/cobicistat-boosted regimens with CYP3A4-metabolized substances — require careful coordination with the prescribing HIV physician.

Conversion practices are illegal in Canada. Bill C-4 (An Act to amend the Criminal Code (conversion therapy), S.C. 2021, c. 24) came into force on January 7, 2022, creating Criminal Code offences for causing a person to undergo conversion therapy (s. 320.102), promoting or advertising it (s. 320.103), and receiving material benefit from providing it (s. 320.104). Psychedelic-assisted therapy must never be used to attempt to change sexual orientation, gender identity, or gender expression. Doing so is both clinically harmful and a criminal offence. ATMA CENA will not provide care to that end and will not accept referrals premised on it. For trans-specific crisis support, Trans Lifeline Canada is reachable at 1-877-330-6366.

For the Canadian affirming-care guide — minority stress in detail, trans-specific considerations, HRT and antiretroviral interactions, chemsex / party-and-play harm reduction, and how to vet a clinic for affirming practice — see our LGBTQ+ psychedelic therapy guide.

Family members and loved ones

When one person enters psychedelic-assisted therapy, the people around them are part of the picture. Spouses, partners, parents, adult children, siblings, and close friends carry their own anxieties about a loved one's care, their own roles in preparation and integration, and — particularly in the older-adult and end-of-life-distress contexts — their own grief and caregiver burden. Family members are not a clinical "afterthought." They are often the people who first raise the question of whether psychedelic-assisted therapy might help.

This population is served by a supporter-oriented guide — what to expect, how to support without intruding, what dosing days and integration look like from the outside, when to step back and when to be present, and where caregiver mental-health resources exist for the supporter themselves. Family-of-choice configurations are part of this picture, particularly in LGBTQ+ contexts.

For families and loved ones supporting a patient through psychedelic-assisted therapy, see our family members and loved ones guide.

Adolescents and young adults — caveat / safety hub

Adolescents (under 18) and young adults (18–25) carry substantial mental-health need — depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, and eating disorders. Suicide is a leading cause of death in Canadian youth.

The pivotal psychedelic-assisted therapy RCT base explicitly excludes patients under 18. Goodwin 2022 (COMP001), Mitchell 2021 (MAPP1), Mitchell 2023 (MAPP2), and Anand 2023 (ELEKT-D) all enrolled adults only. Brain development continues to approximately age 25 — the long-term safety of psychedelic exposure on the developing brain is unknown. Spravato is not Health-Canada-approved for use under 18, and the broader serious-warnings framing on antidepressants in patients under 25 is relevant.

ATMA CENA works with adult populations. Adolescent patients with depression, PTSD, OCD, eating disorders, or treatment-resistant illness should be in specialized adolescent care — SickKids (Toronto), CHEO (Ottawa), BC Children's (Vancouver), CHU Sainte-Justine (Montreal), Stollery (Edmonton), Alberta Children's (Calgary), IWK (Halifax), and provincial child-and-youth mental-health services. First-line evidence-based adolescent treatments are well-established: CBT, IPT-A, family therapy, and fluoxetine (the only SSRI with Health Canada pediatric depression approval) for depression; trauma-focused CBT and EMDR for PTSD; family-based ERP for OCD; family-based therapy (FBT/Maudsley) for eating disorders. Crisis resources for youth and parents include Kids Help Phone (1-800-668-6868; text CONNECT to 686868) and 9-8-8.

For young adults specifically (18–25), inclusion in adult RCTs varies; brain development is still progressing; comprehensive psychiatric assessment, family involvement where the patient consents, and care-setting choice all matter. Chronological age alone is not the sole determinant.

For the full caveat / safety hub — specialized pediatric pathways across Canada, first-line treatments, the limited adolescent ketamine literature (Cullen 2018, Dwyer 2017), provincial age-of-consent framing, and crisis-resource detail — see our adolescents and young adults psychedelic therapy guide.

Healthcare workers and therapists

Healthcare workers — physicians, nurses, paramedics, social workers, allied-health professionals — and psychotherapists and counsellors carry a distinctive occupational mental-health burden. Burnout, moral injury (Litz 2009, Clinical Psychology Review), occupational PTSD (especially in emergency medicine and paramedicine), depression, and substance-use comorbidity are all elevated in this population. The COVID-19 pandemic deepened the pattern that was already present.

A second axis sits in this population: therapists evaluating training to provide psychedelic-assisted therapy themselves — both as a professional development pathway and, in some training programs, with experiential components. The clinical and ethical considerations are distinct from those for healthcare workers seeking psychedelic-assisted therapy as patients, and we treat them separately.

Provincial physician health programs (PHPs) — confidential support and treatment programs for physicians in every province — are often the right entry point for a physician evaluating mental-health care, including psychedelic-assisted therapy. Workers' compensation pathways apply for paramedics, nurses, and other compensable healthcare workers under provincial WSIB / WCB / WorkSafeBC / CNESST frameworks where occupational exposure can be documented.

For the Canadian guide — moral-injury framing, paramedic/PTSD specifics, provincial physician health program pathways, and the therapist-training axis — see our healthcare workers and therapists psychedelic therapy guide.

Pregnancy, postpartum, and lactation — caveat / safety hub

Perinatal depression and anxiety affect approximately one in seven Canadian birthing parents. Postpartum psychosis, peripartum-onset bipolar disorder, perinatal OCD, and birth-related PTSD are clinically important presentations.

Pregnant and breastfeeding patients are explicitly excluded from virtually every pivotal psychedelic-assisted therapy randomized controlled trial. Goodwin 2022, Mitchell 2021/2023, Anand 2023 ELEKT-D, and the Spravato pivotal program all excluded pregnancy and lactation. Controlled human pregnancy and lactation pharmacokinetic data are limited or absent for psilocybin and MDMA. Health Canada product monographs for ketamine and esketamine (Spravato) flag pregnancy and lactation cautions explicitly.

For most patients, psychedelic-assisted therapy is appropriately deferred until after pregnancy and lactation. Standard perinatal psychiatric care is foundational: psychotherapy (CBT, IPT), sertraline as the most-studied SSRI in lactation, and specialized perinatal psychiatry. Bipolar peripartum-onset is common; bipolar contraindication considerations apply to psilocybin and MDMA pathways. Mother-infant bonding is itself a foundational treatment outcome.

For the full caveat / safety hub — Health Canada product-monograph specifics, MotherToBaby teratogenicity framing, CANMAT perinatal mood-disorder guidelines, perinatal crisis resources, family-planning timing for a PAT course, and provincial reproductive psychiatry pathways — see our pregnancy, postpartum, and lactation psychedelic therapy guide.

Disability and accessibility

Approximately 27% of Canadians aged 15 and older have one or more disabilities limiting daily activities, according to the 2022 Canadian Survey on Disability (Statistics Canada). The disability community is not a single population but a constellation of overlapping experiences: physical disabilities, intellectual and developmental disabilities, sensory disabilities (Deaf, blind / low vision), chronic illnesses (multiple sclerosis, ME/CFS, fibromyalgia, Ehlers-Danlos syndromes), traumatic and acquired brain injury (TBI / ABI), and autism-spectrum experiences.

Disability populations carry substantially elevated rates of depression, anxiety, PTSD, and chronic pain comorbidity — and have historically been under-represented in psychedelic-assisted therapy clinical trials. Accessibility is multi-dimensional: physical access (wheelchair, transfer support); sensory access (ASL, LSQ, written communication, tactile orientation); communication access (AAC, plain-language consent); cognitive access (capacity-supportive processes — capacity is decision-specific, and intellectual/developmental disability does not equal incapacity). Sensory considerations during dosing matter for autistic patients and those with sensory processing differences. Service animals must be accommodated under the Accessible Canada Act and provincial human-rights frameworks.

Coverage pathways exist — CPP-D (Canada Pension Plan Disability), ODSP (Ontario), AISH (Alberta), BC PWD, Quebec disability programs, private long-term-disability, VAC, and WSIB / WCB depending on circumstance. Not all clinics are equally accessible. Patients and families are entitled to ask specific accessibility questions before booking.

For the Canadian accessibility guide — population-specific medical considerations, sensory accommodation during dosing, capacity assessment, and coverage detail — see our disability and accessibility psychedelic therapy guide.

Cross-cutting populations: veterans

Canadian veterans — Canadian Armed Forces and RCMP — are a population whose mental-health needs intersect every population guide. Older veterans sit in the older-adults context; Indigenous veterans in Indigenous and culturally-responsive care; trans veterans in LGBTQ+ affirming care; veterans with disabilities (including service-connected TBI) in the disability guide.

The veteran-specific clinical evidence base is the strongest of any population's. Mithoefer 2018 (Lancet Psychiatry) — the phase 2 dose-response trial of MDMA-assisted psychotherapy — enrolled military veterans, firefighters, and police officers with chronic PTSD; active doses (75 mg, 125 mg) were effective and well-tolerated. Mitchell 2021 MAPP1 and Mitchell 2023 MAPP2 are the pivotal phase 3 MDMA-AT trials in severe and moderate-to-severe PTSD, and veterans are a substantial portion of the relevant indication.

Veterans Affairs Canada (VAC) — the federal department providing services and benefits to Canadian veterans — is the most established Canadian psychedelic-coverage pathway for service-related conditions. Off-label ketamine for service-related TRD and chronic pain is well-established. MDMA-AT for service-related PTSD is considered case-by-case. Psilocybin is not VAC-covered. The VAC Mental Health and Wellness hub is the entry point: https://www.veterans.gc.ca/en/health-support/mental-health-and-wellness — and the VAC Assistance Service is reachable 24/7 at 1-800-268-7708.

For Canadian veterans evaluating coverage and care:

VAC coverage for psychedelic-assisted therapy — service-related TRD, PTSD, chronic pain, the VAC pre-authorization pathway, ketamine vs MDMA vs psilocybin coverage detail.
MDMA-assisted therapy for veterans in Canada — Mitchell 2021/2023 and Mithoefer 2018 evidence in detail, SAP route, clinical pathway.

Cross-cutting populations: first responders

First responders — paramedics, firefighters, police officers, correctional officers, dispatchers — carry one of the highest occupational PTSD burdens in Canada. The Mithoefer 2018 phase 2 MDMA-AT trial included police officers and firefighters alongside veterans. Paramedic PTSD is documented at rates substantially above general-population baselines.

Provincial presumptive PTSD legislation is the pivotal coverage variable. Ontario's Supporting Ontario's First Responders Act, 2016 (Bill 163) created a rebuttable statutory presumption of work-relatedness for PTSD diagnosed in first responders, opening the WSIB pathway. Alberta Bill 30 (2017–2018) codified Alberta's first-responder PTSD presumption (firefighters, paramedics, sheriffs, police excluding RCMP). WorkSafeBC, CNESST (Quebec), and several other provincial workers'-compensation systems have their own presumptive frameworks. Coverage of psychedelic-assisted therapy under these pathways is jurisdiction-specific and substance-specific.

For first responders and the lawyers, union representatives, and clinicians supporting them:

First-responder PTSD presumptive legislation in Canada — the provincial legislative landscape.
Workers' compensation and psychedelic-assisted therapy — WSIB Ontario, WCB Alberta, WorkSafeBC, CNESST, and how psychedelic-assisted therapy interfaces with compensable mental-injury claims.

Honest framing — populations providers generally cannot safely serve

We are explicit about the populations for whom psychedelic-assisted therapy as ATMA CENA practises it is not the right fit. This is harm reduction, not gatekeeping.

Patients under 18. Pivotal psychedelic-assisted-therapy RCTs have excluded under-18 populations. Specialized adolescent care is the right pathway. See adolescents and young adults.
Pregnant or actively lactating patients. Standard perinatal psychiatric care is the right pathway in nearly all situations. See pregnancy, postpartum, and lactation.
Patients in active mania. Bipolar disorder, particularly active mania, is a contraindication for serotonergic psychedelics (psilocybin, MDMA). Esketamine and ketamine require specific stabilization framing.
Patients in active psychosis or with primary psychotic disorders. Psilocybin, MDMA, and esketamine pivotal programs excluded primary psychotic disorders and active psychosis.
Patients who are severely medically unstable. Uncontrolled hypertension, unstable cardiovascular disease, recent myocardial infarction or cerebrovascular event, severe hepatic or renal dysfunction, and other situations of acute medical instability are contraindications until stabilized.
Patients without capacity to consent. Capacity is decision-specific and supported decision-making is the appropriate framework where indicated, but informed consent is non-negotiable.
Conversion-practice referrals. Use of psychedelic-assisted therapy to attempt to change sexual orientation, gender identity, or gender expression is illegal in Canada under Bill C-4 and is unconditionally outside the scope of any clinical pathway we offer.

When a population is outside our scope, we say so plainly — and, where possible, route to the appropriate Canadian specialty pathway.

The coordinated care overlay for population-specific care

ATMA CENA's coordinated care model is the structured overlay of preparation, dosing, integration, and continuity of care that wraps every clinical pathway. coordinated care is not a one-size-fits-all script — it adapts to the population. For older adults, that means comprehensive geriatric assessment, polypharmacy review, and family/caregiver integration. For couples, it means structuring preparation and integration as dyadic work. For Indigenous patients, it means practising within a culturally-humble framework that supports — never substitutes for — traditional medicine where the patient chooses to engage both. For LGBTQ+ patients, it means affirming-care defaults embedded throughout. For family members, it means structured supporter pathways alongside the patient's care. For adult-appropriate young adults, it incorporates developmental framing. For healthcare workers and therapists, it includes confidential pathways and provincial physician health program coordination. For patients with disabilities, it embeds accessibility from the first call. For veterans and first responders, it integrates with VAC and workers'-compensation pre-authorization pathways from intake.

For the structural overview of the coordinated care model itself — the four-phase pathway, what preparation, dosing, integration, and continuity look like in practice — see our coordinated care hub.

Frequently asked questions

Who is psychedelic-assisted therapy for in Canada?

Adult Canadians (generally 18 and older) with conditions for which one or more of ATMA CENA's pathways is clinically appropriate — most commonly treatment-resistant depression, post-traumatic stress disorder, end-of-life distress in the context of advanced or terminal illness, and treatment-resistant anxiety — and who are medically and psychiatrically appropriate after assessment.

Is there an upper age limit?

No fixed upper limit. Older adults (65+) are an important population, with specific geriatric-assessment requirements. The pivotal RCT base under-represented this group; honest framing about evidence applicability is part of older-adult care.

Can adolescents under 18 or pregnant patients receive psychedelic-assisted therapy at ATMA CENA?

Generally no for both. Pivotal RCTs excluded under-18 populations and explicitly excluded pregnant and lactating patients; specialized adolescent care and standard perinatal psychiatric care are the appropriate pathways. See the adolescents and young adults guide and the pregnancy, postpartum, and lactation guide.

What about patients with bipolar disorder or a history of psychosis?

Active mania is a contraindication for serotonergic psychedelics (psilocybin, MDMA); stable bipolar I and bipolar II patients require careful population-specific assessment. Primary psychotic disorders and active psychosis are exclusions in psilocybin, MDMA, and esketamine pivotal programs. Both are areas of individualized clinical judgement.

Can LGBTQ+ patients expect affirming care at ATMA CENA?

Yes. Affirming care — pronoun and chosen-name use, WPATH-aligned framing for trans health, family-of-choice integration, trauma-informed pacing — is a baseline standard, not an add-on. Conversion practices are illegal in Canada under Bill C-4 (in force January 7, 2022) and are unconditionally outside our scope.

How does ATMA CENA engage with Indigenous patients and traditional medicine?

We are explicit that clinical psychedelic-assisted therapy and Indigenous traditional medicine are distinct. We do not offer ceremony or traditional knowledge. We offer Health-Canada-regulated and SAP-pathway clinical care within a culturally-humble framework, with respect for Indigenous sovereignty and consent.

What if I'm a veteran or first responder?

For veterans, VAC has the most established psychedelic-coverage pathway for service-related TRD, PTSD, and chronic pain — off-label ketamine has the strongest VAC route; MDMA-AT for PTSD is case-by-case; psilocybin is not covered. For first responders, provincial presumptive PTSD legislation often opens a workers'-compensation pathway; coverage is jurisdiction- and substance-specific. See VAC coverage, MDMA-AT for veterans, first-responder presumptive legislation, and workers' compensation.

What if I have a disability and need accommodations?

Tell us. Communication-preference documentation, ASL/LSQ interpretation, accessible space, sensory accommodations during dosing, capacity-supportive consent processes, and service-animal accommodation are all part of how we work. See the disability and accessibility guide.

Can my partner or family come to my sessions?

Yes, in the right structure. Family/caregiver integration is part of the coordinated care model. Dyadic protocols (where both partners are patients) are a distinct clinical pathway — see couples and dyadic. Family members supporting a patient should also see the family members and loved ones guide.

What if I'm a healthcare worker and concerned about confidentiality?

Provincial physician health programs offer confidential pathways. The therapist-as-patient framing is treated with care. See the healthcare workers and therapists guide.

What if I'm in crisis right now?

Please contact a crisis service before scheduling an information call. 9-8-8 (call or text), Talk Suicide Canada 1-833-456-4566, Hope for Wellness 1-855-242-3310 (Indigenous), Trans Lifeline 1-877-330-6366, Kids Help Phone 1-800-668-6868, or 911 for immediate medical danger.

Sources

Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021;27(6):1025–1033. PMID 33972795. https://pubmed.ncbi.nlm.nih.gov/33972795/
Mitchell JM, Ot'alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 2023;29(10):2473–2480. PMID 37709999. https://pubmed.ncbi.nlm.nih.gov/37709999/
Mithoefer MC, Mithoefer AT, Feduccia AA, et al. MDMA-assisted psychotherapy for PTSD in military veterans, firefighters, and police officers: a phase 2 dose-response trial. Lancet Psychiatry 2018;5(6):486–497. PMID 29728331. https://pubmed.ncbi.nlm.nih.gov/29728331/
Monson CM, Wagner AC, Mithoefer AT, et al. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. Eur J Psychotraumatol 2020;11(1):1840123. PMID 33408811. https://pubmed.ncbi.nlm.nih.gov/33408811/
Wagner AC, Liebman RE, Mithoefer AT, Mithoefer MC, Monson CM. Relational and Growth Outcomes Following Couples Therapy With MDMA for PTSD. Front Psychiatry 2021;12:702838. PMID 34262496. https://pubmed.ncbi.nlm.nih.gov/34262496/
Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med 2023;29:1947–1953. PMID 37488291. https://pubmed.ncbi.nlm.nih.gov/37488291/
Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 2016;30(12):1181–1197. PMID 27909165. https://pubmed.ncbi.nlm.nih.gov/27909165/
Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016;30(12):1165–1180. PMID 27909164. https://pubmed.ncbi.nlm.nih.gov/27909164/
Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression (ELEKT-D). N Engl J Med 2023;388(25):2315–2325. PMID 37224232. https://pubmed.ncbi.nlm.nih.gov/37224232/
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). N Engl J Med 2022;387(18):1637–1648. PMID 36322843. https://pubmed.ncbi.nlm.nih.gov/36322843/
Wajs E, Aluisio L, Holder R, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry 2020;81(3):19m12891. PMID 32316080. https://pubmed.ncbi.nlm.nih.gov/32316080/
Meyer IH. Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull 2003;129(5):674–697. PMID 12956539. https://pubmed.ncbi.nlm.nih.gov/12956539/
Litz BT, Stein N, Delaney E, et al. Moral injury and moral repair in war veterans: A preliminary model and intervention strategy. Clin Psychol Rev 2009;29(8):695–706. PMID 19683376. https://pubmed.ncbi.nlm.nih.gov/19683376/
Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 (WPATH SOC-8). Int J Transgend Health 2022;23(Suppl 1):S1–S259. https://wpath.org/publications/soc8/
An Act to amend the Criminal Code (conversion therapy), S.C. 2021, c. 24 (Bill C-4). Royal assent December 8, 2021; in force January 7, 2022. Department of Justice Charter Statement: https://www.justice.gc.ca/eng/csj-sjc/pl/charter-charte/c4_1.html
Truth and Reconciliation Commission of Canada. Calls to Action (2015). NCTR: https://nctr.ca/about/truth-and-reconciliation-commission-of-canada-calls-to-action/ ; Government of Canada response on health: https://www.rcaanc-cirnac.gc.ca/eng/1524499024614/1557512659251
Health Canada. Regulations Amending Certain Regulations Relating to Restricted Drugs (Special Access Program) (SOR/2022-1). Canada Gazette Part II, Vol. 156, No. 1, January 5, 2022. https://gazette.gc.ca/rp-pr/p2/2022/2022-01-05/html/sor-dors271-eng.html ; Health Canada notice to stakeholders: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Veterans Affairs Canada. Mental Health and Wellness. https://www.veterans.gc.ca/en/health-support/mental-health-and-wellness ; VAC Assistance Service 24/7: 1-800-268-7708.
Supporting Ontario's First Responders Act (Posttraumatic Stress Disorder), 2016, S.O. 2016, c. 4 (Bill 163). https://www.ontario.ca/laws/statute/s16004 ; WSIB operational policy: https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
Government of Alberta. An Act to Protect the Health and Well-being of Working Albertans (Bill 30; 2017–2018) — Workers' Compensation Amendment / OHS Act replacement; codified first-responder PTSD presumption.
Statistics Canada. Canadian Survey on Disability, 2022. https://www150.statcan.gc.ca/n1/daily-quotidien/231201/dq231201b-eng.htm ; Survey program: https://www.statcan.gc.ca/en/survey/household/3251
Hope for Wellness Helpline (Indigenous; 24/7). 1-855-242-3310. https://www.hopeforwellness.ca/ ; Indigenous Services Canada page: https://www.sac-isc.gc.ca/eng/1576089519527/1576089566478
Trans Lifeline Canada. 1-877-330-6366. https://translifeline.org/hotline/
Kids Help Phone. 1-800-668-6868 (24/7); text CONNECT to 686868. https://kidshelpphone.ca/
9-8-8 Suicide Crisis Helpline (Canada). Call or text 9-8-8 (24/7). https://988.ca/ — launched November 30, 2023, operated by CAMH.
Talk Suicide Canada. 1-833-456-4566 (24/7); text 45645 (4 PM–midnight ET). https://talksuicide.ca/
Canadian Coalition for Seniors' Mental Health (CCSMH). Canadian Guidelines on Prevention, Assessment and Treatment of Depression Among Older Adults (2021). https://ccsmh.ca/areas-of-focus/depression/
Roots to Thrive (Nanaimo, BC) — Snuneymuxw First Nation collaboration. https://rootstothrive.com/ ; Indigenous Reconciliation Fund record: https://irfund.ca/en/snuneymuxw-first-nation-collaboration-and-reconciliation-with-roots-to-thrive-program/
TheraPsil (BC; founder Dr. Bruce Tobin). https://therapsil.ca/

Related hubs

Insurance Coverage for Psychedelic-Assisted Therapy in Canada — Canadian insurance landscape, prior authorization, VAC, workers' compensation, RAMQ.
Conditions — Psychedelic-Assisted Therapy in Canada — depression, PTSD, anxiety, end-of-life distress, OCD, and beyond.
How Psychedelic-Assisted Therapy Works at ATMA CENA — preparation, dosing, integration, and continuity of care.

Substance guides

Ketamine-Assisted Therapy in Canada — off-label ketamine and Spravato (esketamine) pathways.
Psilocybin-Assisted Therapy in Canada — Special Access Program pathway, evidence base.
MDMA-Assisted Therapy in Canada — Special Access Program pathway, PTSD focus.

Who We Serve — Psychedelic-Assisted Therapy Across Canadian Populations